Companies Dominating the Plasma Fractionation Landscape
- CSL Limited
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Grifols, S.A.
- Takeda Pharmaceutical Company Limited
- Kedrion S.p.A
- Octapharma AG
- Bio Products Laboratory Ltd.
- Biotest AG
- LFB Group
- Japan Blood Products Organization
- Intas Pharmaceuticals Ltd.
Browse key industry insights with market data tables & charts from the report:
Frequently Asked Questions (FAQ)
Plasma Fractionation Market in 2025 is estimated at USD 31.45 billion.
The global market size was valued at more than USD 29.76 billion in 2024 and is expected to register a CAGR of over 7.1%, exceeding USD 72.59 billion revenue by 2037.
North America is forecast to accumulate majority share by 2037, attributed to high number of hemophilic patients and rising prevalence of chronic diseases.
The major players in the market include CSL Limited, Grifols, S.A., Takeda Pharmaceutical Company Limited, Kedrion S.p.A, Octapharma AG, Bio Products Laboratory Ltd., Biotest AG, LFB Group, Japan Blood Products Organization, Intas Pharmaceuticals Ltd.
